Logo Logo
Help
Contact
Switch Language to German
Bausewein, Claudia (2016): Therapie von Atemnot, Angst und Depression bei fortgeschrittenen Lungenerkrankungen. In: Pneumologe, Vol. 13, No. 3: pp. 166-173
Full text not available from 'Open Access LMU'.

Abstract

Background. Dyspnea, anxiety and depression are common symptoms in patients with advanced lung disease and markedly impair the quality of life of these patients. Objective. Summary of non-pharmacological and pharmacological measures for dyspnea, anxiety and depression based on the available evidence. Material and methods. Analysis of primary studies, reviews and guidelines for the named symptoms and their management. Results. Recognition and assessment are initially essential for the management of dyspnea, anxiety and depression. Various non-pharmacological measures, such as general information, a management plan for coping with dyspnea, use of a handheld fan, physical activity and rollators are available for the management of dyspnea. Opioids are the drugs of choice for intractable dyspnea. Slight to moderate depression should be primarily treated by psychotherapy. Antidepressants are additionally indicated for moderate to severe depression. There is insufficient evidence for the pharmacological treatment of anxiety. Conclusion. Dyspnea, anxiety and depression have a marked impact on the quality of life of patients with advanced lung disease. There are a number of treatment options which can be used to help relieve symptoms.